In Vivo Safety Evaluation Services for Veterinary (Pet) Antibody

Are you navigating the complexities of preclinical safety assessment for your novel pet therapeutic antibodies? The journey from a promising candidate to a safe therapeutic can be fraught with challenges, from unpredictable toxicities to potential immunogenic reactions in target species. Creative Biolabs' in vivo safety evaluation service for veterinary therapeutic antibody development helps you de-risk your development pipeline and build a robust safety profile for regulatory submission. Through our expertly designed animal studies and state-of-the-art analytical platforms, we empower you to make data-driven decisions and accelerate the path to market for your innovative pet therapies.

In Vivo Safety Evaluation Services

Creative Biolabs provides comprehensive in vivo safety and toxicology testing services specifically tailored for veterinary antibody therapeutics. Our goal is to deliver a clear, thorough assessment of your candidate's safety profile in relevant animal models, providing the critical data needed to advance your project with confidence. We translate complex biological responses into actionable insights, ensuring you have a complete picture of your therapeutic's potential effects before moving toward pivotal studies. Our service is structured into two core modules that can be performed sequentially or as standalone studies, depending on your project's needs.

Discover How We Can Help - Request a Consultation

  • In Vivo Toxicological Evaluation
    This service is designed to identify potential target organ toxicities and establish a safe dose range for your therapeutic antibody. We conduct dose-range finding (DRF) and repeat-dose toxicology studies in relevant species (e.g., mice, rats, canines, felines), monitoring a comprehensive set of clinical, hematological, and histopathological endpoints to characterize the No Observed Adverse Effect Level (NOAEL).
  • In Vivo Immunogenicity Evaluation
    Unwanted immune responses can compromise the efficacy and safety of a therapeutic antibody. This evaluation assesses the potential for your antibody to elicit an antibody response in the target species. We utilize highly sensitive immunoassays to detect and characterize antibodies, providing crucial information on the potential for immunogenicity-related adverse events and impact on drug exposure.

Workflow

Ensuring the safety of veterinary therapeutic antibodies is critical before clinical application. Our in vivo safety evaluation service provides comprehensive toxicology and tolerability assessments in relevant animal models, helping you meet regulatory expectations and safeguard animal health.

Antibody In Vivo Safety Evaluation Service Workflow. (Creative Biolabs Original)Fig 1. Pet Antibody In Vivo Safety Evaluation Service Workflow. (Creative Biolabs Original)

Study Design & Protocol Development Collaborate with you to define study objectives, dosing regimens, endpoints, and observation periods. Select the most appropriate animal species and model in alignment with the target pet species and intended clinical use.
Animal Model Development Source healthy, well-characterized animals with relevant physiological and immunological profiles. Acclimate and baseline-assess animals to ensure health status before dosing.
Dosing & Administration The therapeutic antibody candidate is administered to the selected animal models according to the approved protocol.
Sample Collection & Clinical Pathology At specified time points, biological samples are collected for comprehensive analysis. This includes hematology, serum biochemistry, and coagulation panels to assess organ function and systemic health.
Data Analysis & Reporting All data from the in-life, clinical pathology, and histopathology phases are compiled, statistically analyzed, and interpreted. The outcome is a comprehensive, integrated study report that provides a clear conclusion on the safety profile of your antibody.

Why Choose Us?

  • Specialized Veterinary Expertise
    Our team consists of DVMs and Ph.D. scientists with decades of experience specifically in companion animal physiology and toxicology, ensuring your study is designed and interpreted with the target species in mind.
  • Advanced Analytical Platforms
    We employ state-of-the-art technologies for clinical pathology and utilize highly sensitive, validated platforms for immunogenicity assessment, providing you with the most accurate and reliable results.
  • Transparent Communication
    We believe in a collaborative approach, providing regular updates and direct access to our study directors to ensure you are informed at every stage of your project.

Canine PD-L1 antibody production and validation working flow. (Oh, et al., 2023) (OA Literature)Fig 2. Working flow chart for production and validation of the cPD-L1 antibody.1,2

FAQs

1. What animal species can you perform safety studies in?
We routinely conduct studies in standard laboratory models like mice and rats, as well as target companion animal species, including beagles (canines) and domestic shorthair cats (felines). We can discuss custom model requirements to best suit your therapeutic's target. We encourage you to reach out to discuss your specific needs.
2. How does this service integrate with efficacy studies?
Safety data is often evaluated in parallel or sequentially with efficacy studies. Data from our safety evaluations, such as the Maximum Tolerated Dose (MTD) and NOAEL, are crucial for designing relevant and safe dose levels for your pivotal efficacy trials. We can help you coordinate these efforts seamlessly.

Related Services

To fully support your veterinary therapeutic development pipeline, Creative Biolabs also offers a suite of complementary in vivo services.

(Creative Biolabs Authorized)In Vivo Efficacy Evaluation

We help you demonstrate your antibody's therapeutic benefit in validated or custom-developed disease models for companion animals.

(Creative Biolabs Authorized)In Vivo PK/PD Evaluation

Our pharmacokinetic and pharmacodynamic studies characterize the absorption, distribution, metabolism, and excretion (ADME) of your antibody, linking exposure to biological effect.

(Creative Biolabs Authorized)Animal Model Customization

If a standard model doesn't fit your needs, our experts can develop and validate custom animal models to replicate specific disease states in veterinary species.

Partner with Creative Biolabs

Creative Biolabs is dedicated to advancing pet health through rigorous, cutting-edge science. Our in vivo safety evaluation services provide the critical data and expert interpretation you need to confidently move your veterinary antibody therapeutic from the lab to the clinic. We partner with you to navigate the complexities of preclinical development, ensuring a clear path toward regulatory approval.

Ready to build a robust safety profile for your therapeutic candidate? Our team is available to discuss your project in detail and provide a tailored proposal. Contact our team to learn more about our customized solutions for your pet therapeutic antibody in vivo safety evaluation project.

Contact Our Team for More Information and to Discuss Your Project.

References

  1. Oh, Wonkyung et al. "Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans." Cancer research communications vol. 3,5 860-873. 15 May. 2023, https://doi.org/10.1158/2767-9764.CRC-22-0468
  2. Distributed under Open Access license CC BY 4.0, without modification.
Services

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.